Episode
Epigenetic Mechanisms in Breast Cancer (Luca Magnani)
- Podcast
- Epigenetics Podcast
- Published
- Aug 21, 2025
- Duration seconds
- 2262
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/epigenetics-podcast-809637/episodes/epigenetic-mechanisms-in-breast-cancer-luca-magnani/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/epigenetics-podcast-809637/epigenetic-mechanisms-in-breast-cancer-luca-magnani.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of the Epigenetics Podcast, we talked with Luca Magnani from Institute of Cancer Research and UNIMI in Milan about his work on epigenetic mechanisms of drug resistance and cancer cell dormancy in breast cancer. We start the interview by putting our focus on his significant contributions to the understanding of estrogen receptor-positive breast cancer. In a foundational study from 2013, Professor Magnani and his colleagues illuminated the role of genome-wide reprogramming of the chromatin landscape in conferring resistance to endocrine therapy. This research marked a departure from a purely genetic mutation paradigm, proposing instead that epigenetic modifications play a pivotal role in the development of drug resistance. A fascinating part of our conversation centers on the role of pioneer transcription factors, particularly PBX1, in regulating the estrogen receptor's transcriptional response. Professor Magnani explains how PBX1, typically associated with hematopoietic development, influences estrogen receptor activity, thereby shaping the cancer cell's fate and response to treatment. Continuing our exploration, we discuss the critical distinctions between primary and metastatic breast cancer through the lens of epigenetic reprogramming. By analyzing samples from women with breast cancer, Professor Magnani's work identifies specific enhancer usage that marks the transition to a drug-resistant state which was a breakthrough in linking epigenetic alterations to real-world patient outcomes. He emphasizes that the reliance on genetic mutations alone does not adequately explain the mechanisms of drug resistance, pushing the field to consider the epigenetic landscape more deeply. Our conversation also touches on the evolution of experimental techniques. Profe…